Evidence map›Paper›PMID 23715172›Full record

ArticleMucosal immunology2014

Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease.

D C Macdonald, H Singh, M A Whelan, D Escors, F Arce, S E Bottoms, W S Barclay, M Maini, M K Collins, W M C Rosenberg

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Mucosal immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Isolation and In Vitro Culture of Murine and Human Alveolar Macrophages.Journal of visualized experiments : JoVE · 2018
    Article
  12. Article
  13. Long-Term Persistence of Donor Alveolar Macrophages in Human Lung Transplant Recipients That Influences Donor-Specific Immune Responses.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

D C MacdonaldDivision of Infection and Immunity and MRC Centre for Medical Molecular Virology, University College London, London, UK.
H SinghDivision of Infection and Immunity and MRC Centre for Medical Molecular Virology, University College London, London, UK.
M A WhelanDivision of Medicine, University College London, London, UK.
D EscorsDivision of Infection and Immunity and MRC Centre for Medical Molecular Virology, University College London, London, UK.
F ArceDivision of Infection and Immunity and MRC Centre for Medical Molecular Virology, University College London, London, UK.
S E BottomsDivision of Medicine, University College London, London, UK.
W S BarclayDivision of Virology, Imperial College London, St Mary's Campus, London, UK.
M MainiDivision of Infection and Immunity and MRC Centre for Medical Molecular Virology, University College London, London, UK.
M K CollinsDivision of Infection and Immunity and MRC Centre for Medical Molecular Virology, University College London, London, UK.
W M C RosenbergDivision of Medicine, University College London, London, UK.
University College London · GBMRC Laboratory for Molecular Cell Biology · GBImperial College London · GB

Funding

Medical Research Council G0900374
6 · The paper itself

Abstract

Vaccines that induce T cells, which recognize conserved viral proteins, could confer universal protection against seasonal and pandemic influenza strains. An effective vaccine should generate sufficient mucosal T cells to ensure rapid viral control before clinical disease. However, T cells may also cause lung injury in influenza, so this approach carries inherent risks. Here we describe intranasal immunization of mice with a lentiviral vector expressing influenza nucleoprotein (NP), together with an NFκB activator, which transduces over 75% of alveolar macrophages (AM). This strategy recalls and expands NP-specific CD8+ T cells in the lung and airway of mice that have been immunized subcutaneously, or previously exposed to influenza. Granzyme B-high, lung-resident T-cell populations persist for at least 4 months and can control a lethal influenza challenge without harmful cytokine responses, weight loss, or lung injury. These data demonstrate that AM can be harnessed as effective antigen-presenting cells for influenza vaccination.

Indexed as

Immunologic MemoryAdoptive TransferAnimalsCD8-Positive T-LymphocytesCell LineCross ReactionsCytokinesEpitopes, T-LymphocyteFemaleGene ExpressionGene OrderGenetic VectorsHumansImmunizationImmunization, SecondaryInfluenza A virusCytokinesEpitopes, T-Lymphocyte

Identifiers

PMID23715172
OpenAlexW2003537061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.